home All News open_in_new Full Article

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) — Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating treatment with KH658 […]


today 27 h. ago attach_file Science

attach_file Events
attach_file Other
attach_file Science
attach_file Other
attach_file Other
attach_file Science
attach_file Economics
attach_file Science
attach_file Other
attach_file Events
attach_file Science
attach_file Science
attach_file Science
attach_file Science
attach_file Science
attach_file Other
attach_file Events
attach_file Society
attach_file Events
attach_file Other


ID: 2392341234
Add Watch Country

arrow_drop_down